全文获取类型
收费全文 | 123篇 |
免费 | 11篇 |
专业分类
基础医学 | 10篇 |
临床医学 | 3篇 |
内科学 | 72篇 |
神经病学 | 1篇 |
特种医学 | 1篇 |
外国民族医学 | 1篇 |
外科学 | 7篇 |
预防医学 | 2篇 |
药学 | 2篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 1篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 5篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 4篇 |
2013年 | 3篇 |
2012年 | 8篇 |
2011年 | 11篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 12篇 |
2006年 | 9篇 |
2005年 | 10篇 |
2004年 | 10篇 |
2003年 | 3篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 2篇 |
1996年 | 1篇 |
1995年 | 3篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1978年 | 1篇 |
排序方式: 共有134条查询结果,搜索用时 46 毫秒
1.
2.
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jasmin Bahlo Sandra Kluth Christina Rhein Paula Cramer Carolin Gross‐Ophoff Petra Langerbeins Anna‐Maria Fink Barbara Eichhorst Karl‐Anton Kreuzer Norbert Fischer Eugen Tausch Stephan Stilgenbauer Sebastian Böttcher Hartmut Döhner Michael Kneba Martin Dreyling Mascha Binder Michael Hallek Clemens‐Martin Wendtner the German CLL Study Group 《European journal of haematology》2016,97(3):253-260
3.
4.
Martin Dreyling Armando Santoro Luigina Mollica Sirpa Leppä George Follows Georg Lenz Won Seog Kim Arnon Nagler Maria Dimou Judit Demeter Muhit Özcan Marina Kosinova Krimo Bouabdallah Franck Morschhauser Don A. Stevens David Trevarthen Javier Munoz Liana Rodrigues Florian Hiemeyer Ashok Miriyala Jose Garcia-Vargas Barrett H. Childs Pier Luigi Zinzani 《American journal of hematology》2020,95(4):362-371
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with histologically confirmed indolent B-cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression-free survival, and overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively. Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors. 相似文献
5.
Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell 总被引:6,自引:0,他引:6
Katzenberger T Lohr A Schwarz S Dreyling M Schoof J Nickenig C Stilgenbauer S Kalla J Ott MM Müller-Hermelink HK Ott G 《Blood》2003,101(2):699-702
CD5(+) diffuse large B-cell lymphomas (DLBLs) have recently been described as a particular subgroup of DLBLs. Classical banding and interphase cytogenetic analyses targeting ATM, TP53, and P16(INK4a) genes and the D13S25 locus from 13 CD5(+) DLBLs were compared with 55 CD5(-) DLBLs. Additionally, analysis of somatic mutations of the immunoglobulin heavy chain variable region (IgVH) genes were performed in CD5(+) DLBLs. CD5(+) DLBLs were somatically mutated (7 of 8 cases) and were negative for t(11;14)(q13;q32) and t(14;18)(q32;q21), whereas t(3;14)(q27;q32) was found in only one tumor. Trisomy 3 and gains on chromosomes 16/16p and 18/18q were significantly overrepresented in CD5(+) DLBLs. No ATM deletions were detected. The prevalence of deletions at the D13S25 locus was significantly higher in CD5(+) DLBLs (4 of 12 [33%]) compared with CD5(-) DLBLs (4 of 42 [10%]), as were p16(INK4a) deletions (33% versus 8%). On the basis of these findings, CD5(+) DLBLs are likely to arise from the same progenitor cell as the mutated variant of CD5(+) lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (B-CLL). 相似文献
6.
Hutter G Nickenig C Garritsen H Hellenkamp F Hoerning A Hiddemann W Dreyling M 《The hematology journal : the official journal of the European Haematology Association / EHA》2004,5(1):61-68
The availability of the complete sequence of human mitochondrial DNA (mtDNA) has proven extremely useful in phylogenetic studies, forensic science and the determination of chimerism after allogeneic stem cell transplantation. In this study, we could demonstrate that the analysis of mtDNA polymorphisms is a quick and reliable method to identify contamination of human hematopoietic cell lines. This assay is based on PCR-sequencing of three hypervariable segments of the control region of mtDNA (hypervariable region (HRV) 1, 2 and 3). All three regions contain a large number of single-base polymorphisms. mtDNA was isolated according to standard laboratory procedures and amplified by PCR. Subsequently products were sequenced and evaluated with a semiautomated DNA sequencer system. So far, 21 human leukemia-lymphoma (LL) cell lines and nine other human cell lines were screened for contamination by other cell lines applying this method. We conclude that analysis of mtDNA polymorphisms is a quick, reliable and inexpensive method to detect intra - and interspecies cross-contamination and for the authentication of human LL cell lines. In comparison to other methods (cytogenetics, fluorescence in situ hybridization or immunophenotyping), this technique is less laborious and time consuming. 相似文献
7.
Moderne molekulare und immunologische Techniken haben in den letzten Jahren zunehmende Einblicke in die Pathogenese maligner
Lymphome er?ffnet und damit die Grundlage für eine bessere Charakterisierung und Definition dieser Erkrankungen geschaffen.
Diese Entwicklung spiegelt sich in der neuen Klassifikation der malignen Lymphome durch die WHO wider, die die bisher konkurrierenden
Einteilungen nach der Working Formulation und der Kiel Klassifikation abgel?st hat und erstmals eine weltweit akzeptierte Systematik darstellt [1]. In der WHO Klassifikation wird insbesondere
die früher gebr?uchliche Einteilung in die Gruppen der hoch malignen und niedrig malignen Lymphome verlassen und stattdessen
eine Definition der einzelnen, histologisch, klinisch und biologisch definierten Entit?ten vorgenommen. Diese Klarstellung
stellt einen wesentlichen Fortschritt dar, da sie eine genauere Bewertung einzelner Therapiemodalit?ten für klar definierte
Entit?ten auf internationaler Ebene erlaubt. Die follikul?ren Keimzentrumslymphome stellen nach den gro?zelligen B-Zell-Lymphomen
die zweith?ufigste Entit?t nodaler Lymphome dar und sind daher von hoher klinischer und praktischer Relevanz [2]. 相似文献
8.
Jin M K, Hoster E, Dreyling M, Unterhalt M, Hiddemann W & Klapper W(2011) Histopathology 58 , 586–592 Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome Aims: Follicular dendritic cells (FDC) are specialized antigen‐presenting cells found exclusively in the germinal centre (GC), which can be detected in B cell non‐Hodgkin lymphomas (NHL) as reactive bystander cells. Recently, gene expression profiling has revealed that FDC networks might be associated with clinical outcome in follicular lymphoma. The aim was to characterize FDC in NHL and to evaluate a possible association with outcome in follicular lymphoma. Methods and results: The extent and immunophenotype of FDC was determined semi‐quantitatively in reactive GC and NHL (follicular lymphoma, angioimmunoblastic T cell lymphoma, mantle cell lymphoma) using fluorescence double staining and digital image analysis. In all NHL tested CD23 and CD35 and CD54 were expressed at relatively low levels on FDC, comparable to FDC found in the dark zone of the GC. However, the extent of FDC networks did not correlate with the clinical outcome of 102 patients with follicular lymphomas treated within a prospectively randomized trial. Conclusions: FDC found in different types of NHL show quantitatively reduced expression of several proteins, suggesting that there are functional differences between FDC in normal GC and NHL. The extent of the FDC networks in follicular lymphoma is not useful as a prognostic marker. 相似文献
9.
Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available
therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20
monoclonal antibody immunotherapy. The goals of treatment include prolongation of survival and effective palliation of symptoms
while limiting the duration of therapy to minimize adverse effects and reduce costs. Multiple rounds of treatment over many
years characterize the clinical course for most patients with FL. Rituximab in combination with chemotherapy has been shown
to improve overall survival in patients with FL compared with chemotherapy alone. Rituximab maintenance further improves disease
control in patients with FL after a successful induction therapy in both first-line treatment and relapse. Consolidation with
radioimmunotherapy is an innovative treatment approach to increase rates of complete remission and duration of remission.
Here we summarize the data from actual trials and the resulting treatment indications. 相似文献
10.
Francesco D’Amore John Radford Thomas Relander Mats Jerkeman Hervé Tilly Anders Österborg Franck Morschhauser Martin Gramatzki Martin Dreyling Bo Bang Hans Hagberg 《British journal of haematology》2010,150(5):565-573
The efficacy and safety of zanolimumab (HuMax‐CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty‐one adult patients with relapsed or refractory CD4+ PTCL of non‐cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL‐not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single‐arm multi‐centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26–85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III–IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL‐NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor‐prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated. 相似文献